This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in the French population using serological tests and to assess the determinants of infection from Constances, E3N-E4N, ELFE-Epipage 2 and NutriNet-Santé cohorts.
The primary objective is to assess the cumulative incidence of infection in the general
population using dried blood spot sampling.
The secondary objectives are:
- To identify factors associated with a positive SARS-CoV-2 infection (positive serology)
and to characterize the durability of the serological response to SARS-CoV-2
- To identify associations of symptoms predictive of a SARS-CoV-2 infection
- To estimate the health care use associated with a SARS-CoV-2 infection
- To estimate the fraction of sub-clinical infections or infections not captured by the
healthcare system;
- To study the acceptability of a mass anti-SARS-CoV-2 serological testing and the impact
of its result, linked with social inequalities in health;
- To estimate the individual and collective impact of containment and other preventive
measures on the risk of SARS-CoV-2 infection;
- To study the impact of social and territorial inequalities on seroprevalence levels.
Biological: Non applicable
to collect data from questionnaires and to collect serological samples
Inclusion Criteria:
- non applicable, already enrolled in the cohorts
Exclusion Criteria:
- non applicable
Inserm
Paris, France
Investigator: Fabrice Carrat
Fabrice Carrat
+33 (0)1 44 73 84 44
fabrice.carrat@inserm.fr
Fabrice Carrat, MD, Principal Investigator
Inserm - Sorbonne Université